Benchling, a cloud technology provider to the biotechnology industry, has raised $100 million in Series F funding round at a $6.1 billion valuation.

Benchling said it will use the funding to continue its European expansion and to further develop its cloud-based R&D platform.

The company claims its platform helps biotechnology companies bring medicines, food, and materials to market faster.

Benchling said it already has 90 customers in Europe, including Alchemab Therapeutics, bit.bio, Cutiss AG, Galapagos NV, Kolibri, Lesaffre, PetMedix, Sanofi, Selexis SA, Syngenta, and TATAA Biocenter.

Benchling expects to expand its European headquarters in Zurich and double its headcount in Europe – which is currently 60 - across all customer-facing functions, including sales, services, marketing, and support.

“Biotechnology is rewriting life as we know it. Europe is at the forefront of cutting-edge R&D and we are honoured to work with nearly 100 companies there, after establishing a presence in Zurich last year. We are excited to double down our investment in this important market,” said Sajith Wickramasekara, chief executive and co-founder of Benchling. “Our customers, spanning nearly every major industry, are engineering more effective medicines, nutritious foods, and sustainable crops, materials, and fuels to address humanity’s most pressing issues.”

She added: “These challenges are global, so growth outside of the US is a strategic priority for us as we power modern, data-driven, and collaborative R&D.”

Share Story: